How frequently must a white blood cell count (WBC) be monitored for a patient on Clozaril?

Monitoring white blood cell count (WBC) in patients taking Clozaril (clozapine) is crucial due to the risk of agranulocytosis, a potentially severe side effect that can lead to a dangerously low white blood cell count. The recommended protocol for patients starting treatment with Clozaril includes frequent blood monitoring to ensure that the WBC remains within a safe range.

The correct answer indicates that WBC counts should be monitored once a week for the first month. This is necessary because during the initial phase of treatment, the risk of drop in WBC is highest, and close monitoring helps identify any significant changes promptly. After this initial period, the monitoring frequency may change based on the individual patient's response and risk factors, but for the beginning of treatment, weekly checks are essential for patient safety.

In subsequent months, the frequency can be adjusted to less often depending on the patient's WBC stability and overall health condition, but the initial weekly checks for at least the first month are a critical safety measure.